Company Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Healthcare Facilities & Services

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Mainz Biomed N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8181 ^USD	-4.52%		-9.60%	-29.47%

Apr. 25	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	CI
Apr. 09	Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Number of employees: 68

USD in Million	2022	Weight	2023	Weight	Delta
Genetic Diagnostic Testing 100.0 %	1	100.0 %	1	100.0 %	+69.00%

USD in Million	2022	Weight	2023	Weight	Delta
Germany 100.0 %	1	100.0 %	1	100.0 %	+69.00%

Managers	Title	Age	Since
Guido Baechler CEO	Chief Executive Officer	59	21-06-30
William Caragol DFI	Director of Finance/CFO	58	21-06-30
Corinna Gorges CTO	Chief Tech/Sci/R&D Officer	-	21-10-31
Frank Krieg-Schneider CTO	Chief Tech/Sci/R&D Officer	-	22-08-02
Moritz Eidens CTO	Chief Tech/Sci/R&D Officer	41	-
Stefan Erlach HRO	Human Resources Officer	-	-
Amy Levin LAW	General Counsel	-	22-11-28
Jane Edwards PRN	Corporate Officer/Principal	-	22-06-13
Steve Quinn PRN	Corporate Officer/Principal	-	22-01-26
Philipp Freese PRN	Corporate Officer/Principal	42	15-01-31

Members of the board	Title	Age	Since
Gregory Tibbitts BRD	Director/Board Member	57	22-12-13
Heiner Dreismann CHM	Chairman	69	22-12-13
Hans Johan Hekland BRD	Director/Board Member	66	21-10-31
Guido Baechler CEO	Chief Executive Officer	59	21-06-30
Moritz Eidens CTO	Chief Tech/Sci/R&D Officer	41	-
Nicole Holden BRD	Director/Board Member	51	21-10-31
Alberto Libanori BRD	Director/Board Member	35	21-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,886,575	17,151,888 ( 78.37 %)	0	78.37 %

Name	Equities	%	Valuation
Government of Germany 7.389 %	1,237,501	7.389 %	1 M $
Moritz Eidens 6.725 %	1,126,348	6.725 %	1 M $
Guido Baechler 4.492 %	752,357	4.492 %	774 928 $
Hans Johan Hekland 4.280 %	716,873	4.280 %	738 379 $
Philipp Freese 2.161 %	361,972	2.161 %	372 831 $
William Caragol 1.270 %	212,677	1.270 %	219 057 $
Darin Leigh 0.6892 %	115,417	0.6892 %	118 880 $
Heiner Dreismann 0.5255 %	88,000	0.5255 %	90 640 $
Prelude Capital Management LLC 0.4478 %	75,000	0.4478 %	77 250 $
Nicole Holden 0.2090 %	35,000	0.2090 %	36 050 $

Mainz Biomed NV

Sirius Gutenberg Park Robert Koch Strasse 50

55129, Mainz

+49 6131 554 2860

http://mainzbiomed.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8181 USD

Average target price

2 USD

Spread / Average Target

+144.47%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
MAINZ BIOMED N.V.	-29.47%	17.91M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories